Indication
Systemic Mastocytosis
10 clinical trials
15 products
1 drug
Product
TL-895Clinical trial
A Phase 2 Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic MastocytosisStatus: Recruiting, Estimated PCD: 2025-06-30
Product
PlaceboClinical trial
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid MalignanciesStatus: Completed, Estimated PCD: 2022-10-05
Clinical trial
GTB-3550 (CD16/IL-15/CD33)Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic MastocytosisStatus: Terminated, Estimated PCD: 2021-08-02
Product
GTB-3550 TriKEProduct
AvapritinibClinical trial
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard TherapyStatus: Active (not recruiting), Estimated PCD: 2027-06-23
Clinical trial
Phase 3 Study to Compare Oral Masitinib to Placebo in Treatment of Patients With Smouldering or Indolent Severe Systemic Mastocytosis, Unresponsive to Optimal Symptomatic TreatmentStatus: Recruiting, Estimated PCD: 2024-12-01
Product
MasitinibProduct
BLU-263Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic MastocytosisStatus: Recruiting, Estimated PCD: 2028-06-30
Clinical trial
A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological MalignanciesStatus: Active (not recruiting), Estimated PCD: 2026-05-05
Product
AcetaminophenProduct
DexamethasoneProduct
DiphenhydramineProduct
FlotetuzumabProduct
IbuprofenProduct
RanitidineClinical trial
A Phase 2 Randomized Double-Blinded Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in Subjects With Indolent Systemic MastocytosisStatus: Completed, Estimated PCD: 2023-07-31
Product
sarilumabClinical trial
Evaluation of RAD001 as Therapy for Patients With Systemic MastocytosisStatus: Completed, Estimated PCD: 2009-10-01
Product
RAD001Clinical trial
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic MastocytosisStatus: Completed, Estimated PCD: 2024-03-11
Product
DenosumabDrug
Varlilumab